As the field celebrates the world’s first self-amplifying mRNA vaccine approval from CSL and Arcturus Therapeutics, and huge investments such as the $270 million raised by Orbital Therapeutics, the field of next generation RNA therapeutics emerges as a preferred RNA platform, with circular RNA, self-amplifying RNA and transfer RNA offering potential for improved stability, longevity, and increased therapeutic potential.

The 3rd Next Generation RNA Therapeutics Summit returns to Boston to cover the depth and breadth of circular RNA, self-amplifying RNA (saRNA) and transfer RNA, from discovery to clinic and towards scalable manufacturing, equipping RNA leaders with strategic insights to fast-track these therapies into the clinic unlocking the huge therapeutic and commercial potential of this emerging class of medicines.

Event Link here.